Latest App Notes & Case Studies

Pyruvate kinase is an enzyme involved in energy-supplying glycolysis and ATP synthesis, thus is pivotal for the eucaryotic energy metabolism. In addition, overexpression of pyruvate kinase is believed to play a role in cancer.

One of the major challenges faced by most toxicology laboratories is analyzing hundreds of drugs of abuse in biological samples. This is further complicated by the constantly increasing emergence in the volume of designer and illicit drugs.

RTP004 is a proprietary peptide used by Revance Therapeutics as a novel excipient in DaxibotulinumtoxinA for injection. Due to its high molecular weight, high isoelectric point and strong non-specific binding property, the sample preparation and LC-MS method development for this peptide is very challenging.

In early-stage pharmaceutical research, knowledge of a compound’s metabolism can assist in the identification of structural liabilities that can contribute to non-optimal pharmacokinetics, potentially toxic breakdown products or the potential for drug-drug interactions.

In quantifying therapeutic peptides and proteins in biological matrices, traditional ELISA-only based techniques can suffer from high variability, narrow dynamic range, problems with selectivity and typically cannot use internal standards.

Sample preparation and alternative chromatography techniques are often used to meet the sensitivity needs required in routine bioanalytical assays, but these methods can be time consuming.

In biotherapeutic development, decreased drug doses and limited sample volumes require higher quantification sensitivity, while the complexity of biological matrices calls for the need of assay selectivity improvement.

Demands for improved sensitivity in routine bioanalytical assays continue to increase as drug discovery and development programs focus on more efficacious, lower dosage compounds. Pharma development scientists supporting this work therefore require highly sensitive and selective bioanalytical methods for quantification.

It has proven difficult to accurately identify the biological targets of cancer, which are necessary for the development of successful therapeutics including novel immunotherapies, such as those based on chimeric antigen receptor (CAR) T cells.

One approach to develop drugs for infectious diseases involves a comprehensive understanding of human-pathogen protein interactions, as targeting host proteins helps reduce the possibility of drug resistance by creating a more significant evolutionary barrier for the virus.